Given that in AML patients the ABCB1 expression is linked to a worse prognosis [49], we hypothesise that NBEAL2 deletion or inactivating NBEAL2 mutations could be a prognostic marker for dysregulated ABCB1 on the cell surface and the resulting tolerance development of cancer cells to chemotherapeutic treatments. This evidence concerns the gene ABCB1 and cancer.